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Abstract
Background
Aspirin is widely used for prevention of cardiovascular disease. In recent years randomized
trials also suggested a preventive effect for various types of cancer. We aimed to assess, in
a quantitative way, benefits and harms of aspirin for primary prevention of both cardiovascu-
lar disease and cancer for a general US population between 40 and 85 years of age.
Methods
We used the Gail/National Cancer Institute approach for assessing benefits and harms.
This approach provides a probability that a treatment is more beneficial than harmful and
incorporates multiple outcomes, the importance of these outcomes, considers different out-
come risks and treats mortality as a competing risk. Our main outcomes were the risks of
seven types of cancer, myocardial infarction, ischemic and hemorrhagic stroke and gastro-
intestinal bleeding. We obtained effect estimates from recent meta-analyses of randomized
trials and used baseline risks from the Centers for Disease Control. We conducted four sen-
sitivity analyses to assess the influence of different assumptions about outcome risks and
preferences and considered the sampling variation of the effect estimates for aspirin.
Results
The main analysis as well as the sensitivity analyses showed that aspirin has more benefits
than harms. In the main analysis, the index (positive if number of prevented events > excess
number of harm events over 10 years per 1,000 persons) ranged from 2 (95% CI 0.0 to
11.8; in women age 45 to 54 years) to 8 (95% CI -0.1 to 83.7; in men age 65 to 74 years). In
the sensitivity analyses, the index was also positive for all age categories suggesting more
benefits than harms.
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Conclusion
This study suggests an overall benefit of aspirin for primary prevention of cardiovascular
disease and cancer based on population-based data. For individual preventive counseling,
additional benefit harm analyses should explore which individuals should or should not take
aspirin based on their risk profile for cardiovascular, cancer and gastrointestinal outcomes
and based on their outcome preferences. Thereby, risk-stratified and preference-sensitive
prevention could become a reality.
Background
Cardiovascular disease (CVD) and cancer contribute substantially to morbidity and mortality
in developed countries. In the USA, cancer incidence rates were 963 per 100,000 persons for
55–59 year olds in 2008, and 2,994 per 100,000 persons for 80–84 year olds. [1,2] Cardiovascu-
lar disease accounts for approximately 33% of all deaths in the US. [3–5]Primary prevention of
cardiovascular disease and cancer has become an important public health goal. Contemporary
preventative measures are often multifaceted and may include life style modification such as
increasing physical activity and modifying diet, smoking cessation and drug treatments such as
aspirin. [6,7]
While low dose aspirin is widely used in clinical practice for secondary prevention after
myocardial infarction and stroke [8–16], low-dose aspirin is increasingly used as a primary pre-
vention measure for cardiovascular disease.[1,8,9] The U.S. Preventive Services Task Force
made recommendations about primary prevention for individual patients without cardiovas-
cular disease to prevent stroke and cardiovascular events. [3,5,9] In recent years, the role of
aspirin to prevent cancer has also been discussed. Evidence from recent meta-analyses of pri-
mary prevention cardiovascular disease trials showed a reduction in cancer incidence, risk for
metastasis and cancer specific mortality in aspirin users. These meta-analyses of trials compar-
ing aspirin versus placebo were assessed in order to evaluate the effect of aspirin on major car-
diovascular events or stroke in adults[1,8–11,13,14,19]
Despite these benefits, the use of aspirin as a primary prevention measure also has its down-
sides. Because of the anti-clotting effect, gastrointestinal bleeding is one of the most common
complications of long term aspirin use.[1,10] Aspirin inhibits the COX-1 enzyme thereby
reducing the synthesis of prostaglandins. As a consequence, the gastric mucosa is less protected
from acid-induced damage, and the relative risk of gastric bleeding in aspirin users is 1.62(95%
confidence interval (CI), 1.31, 2.00). [1] Hemorrhagic stroke is another rare but potentially
severe complication of long-term aspirin use.[5,8,11] In 2005, 23% of 45 to 64 year olds without
heart disease in the US took aspirin on a daily or every other day basis.[9] In the category 65
and older this percentage was even higher (41%) despite the fact that it is still unclear whether
aspirin for primary prevention provides more benefits than harms. [9,12–16]
Quantitative approaches for developing recommendations can be particularly helpful if the
benefit-harm balance is difficult to judge. This is often the case when baseline risks for benefit
and harm outcomes vary substantially, when the importance of outcomes vary and when there
are competing events such as mortality.[17] Our aim was to assess the benefits and harms of
aspirin for primary prevention of both cardiovascular disease and cancer in the general popula-
tion between 40–85 years of age.
A Benefit and Harm Analysis
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Methods
Approach
We specified a population-based decision making context from the perspective of a hypotheti-
cal guideline-maker. We wanted to assess the benefits and harms of low dose aspirin compared
to no aspirin for primary prevention of cancer and cardiovascular disease. The target popula-
tion was defined as the adult population without evidence of cardiovascular disease, stroke or
cancer, between 40 and 85 years of age. We made separate analyses for men and for women,
and allowed estimates of baseline risk of the assessed outcomes to vary with age.
The beneficial outcomes were prevented cases of myocardial infarction, major ischemic
stroke and cancer (benefits). The harms were major hemorrhagic stroke and major bleeding,
which is primarily gastrointestinal bleeding. The time horizon was 10 years. Death from any
cause was considered as a competing risk.
We used the Gail/National Cancer Institute approach for assessing benefits and harms. This
approach provides a probability that a treatment is more beneficial than harmful and incorpo-
rates multiple outcomes, outcome risks and the importance of outcomes and is therefore more
comprehensive in terms of considering multiple data sources than other approaches.[1,18–20]
The code can be requested by contacting the corresponding author.
Data Sources
Cardiovascular disease. We used the summary estimates of a random effects meta-analy-
sis for primary prevention of cardiovascular disease by aspirin.[1,8] This study reported a rela-
tive risk (RR) of 0.86 (95% CI 0.74;1.00) for myocardial infarction, RR of 0.87 (95% CI
0.73;1.02) for ischemic stroke, RR of 1.35 (95% CI 1.01;1.81) for hemorrhagic stroke, and RR of
1.62 (95% CI, 1.31;2.00) for gastrointestinal bleeding for aspirin compared to placebo
(Table 1).
Cancers. For colorectal, lung, esophageal, pancreatic, stomach, prostate, breast and blad-
der cancer, we used the results from a large trial on the effects of aspirin on cancer incidence.
[1,13,16,21–25]. This study reported a hazard ratio (HR) for colorectal cancer of 0.63 (95% CI
0.47;0.85), a HR for lung cancer of 0.96 (95% CI 0.70;1.32), a HR for esophageal cancer of 0.76
(95% CI 0.38;1.53), a HR for pancreatic cancer of 1.07 (95% CI 0.59;1.94), a HR for stomach
cancer of 1.01 (95% CI 0.54;1.86), a HR for bladder cancer of 0.94 (95% CI 0.64;1.38), a HR for
prostate cancer of 0.87 (95% CI 0.69;1.10) and a HR for breast cancer of 0.90 (95% CI
0.26;3.07). (Table 1)
Outcome risks
Baseline Risks Cardiovascular disease. Table 1 shows the estimated incidence rates with-
out aspirin for cancer, cardiovascular disease and gastrointestinal-bleeding. We used data from
the Atherosclerosis Risk in Communities Study, a prospective epidemiologic study conducted
in four U.S. communities, to obtain baseline incidence rates of myocardial infarction and
stroke without treatment. [5,9,11,26] These data are used by the National Heart, Lung & Blood
Institute to report trends on the incidence of cardiovascular disease. No reliable data were
available for men in the age category 75–84 years. To estimate the incidence rate we assumed a
50 percent increase from age category 65–74 years based on similar increases in incidences in
age category 65–74 to 75–84 years in the Framingham Heart Study and the Cardiovascular
Health Study. [27,28]
Since we were unable to find appropriate population-based estimates of gastrointestinal
bleeding in the US population we relied, similar to what was done by the U.S. Preventive
A Benefit and Harm Analysis
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Services Task Force in their aspirin guideline, on estimates from the General Practice Research
Database, a database from the United Kingdom, and the Base de Datos para la Investigacion
Farmacoepidemioloica en Atecion Primaria from Spain. This report provided information
about the prevalence of risk factors for severe GI bleeding (age, sex, prior GI history) and inci-
dence rates for severe GI bleeding for several age and sex categories. For our four age categories
we calculated the incidence of severe GI bleeding. [29,30] To estimate the all-causes risk of
death we relied on estimates from the Center for Disease Control. [31] We made no correction
for double counting of causes of death.
Baseline risks cancer. Table 1 shows the estimates of the incidence rates without aspirin
for the types of cancer in our study based on data from the Centers for Disease Control. [12–
16,25]
Table 1. Data for benefit-harm assessment. Treatment effects and outcome risks.
Incidence rates cardiovascular disease and gastrointestinal-
bleeding (per 10,000 persons) without aspirin based on
surveillance data
Relative Risk with aspirin (95%
CI)
Incidence rates in men Incidence rates in women
45–
54
55–
64
65–
74
75–
84
45–
54
55–
64
65–
74
75–
84
Myocardial infarction 0.86 (0.74;1.00) 40 62 93 140* 12 30 47 82
Major ischemic stroke 0.87 (0.73;1.02) 12 25 56 108 9.0 20 36 75
Major hemorrhagic stroke 1.35 (1.01;1.81) 2.0 4.0 8.0 16 1.0 3.0 5.0 11
Major gastrointestinal bleeding 1.62 (1.31;2.00) 12 25 49 80 6.0 12 23 37
All-cause mortality 50 100 250 670 30 70 160 480
Incidence rates cancer (per 10,000 persons)
Colorectal cancer 0.63 (0.47;0.85) 9.5 21.5 44.7 65.5 12.5 15 30.5 50.4
Lung cancer 0.96 (0.70;1.32) 9.5 32.7 82.3 114 8.1 24.1 57.3 68.4
Bladder cancer 0.94 (0.64;1.38) 3.3 11.8 32.0 58.0 1.2 3.3 7.9 13.3
Stomach cancer 1.01 (0.54;1.86) 1.0 3.7 7.8 11.7 0.8 1.6 3.4 5.9
Pancreas cancer 1.07 (0.59;1.94) 2.0 5.6 11.9 17.4 1.3 3.8 8.7 14.7
Oesophagus cancer 0.76 (0.38;1.53) 1.5 4.4 7.7 9.8 0.3 0.8 1.7 2.5
Prostate cancer (men)Breast cancer
(women)
0.87 (0.69;1.10) 0.90 (0.26;3.07) 20.3 92.6 182.7 153.8 12.8 16.4 19.8 15.6
Cancer overall men/women 0.75 (0.59;0.94) 0.77 (0.63;0.93) 86.2 219.1 500.7 620 100.9 180.9 299 373.4
Incidence rates (per 10,000 persons) without aspirin. For sensitivity analyses 4, with RCT data.
Mean ages 53–64 years.
Men Women
Myocardial infarction 56 10
Major ischemic stroke 21 11
Major hemorrhagic stroke 3.0 2.0
Major gastrointestinal bleeding 9.0 5.0
All-cause mortality 79 34
* No reliable data was available from the Atherosclerosis Risk in Communities Study for men in age category 75–84 years. To estimate the incidence rate
we assumed a 50 percent increase from age category 65–74 years based on similar increases in incidences in age category 65–74 to 75–84 in the
Framingham Heart Study and the Cardiovascular Health Study.
doi:10.1371/journal.pone.0127194.t001
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Assumptions
To perform the benefit-harm analyses a number of additional assumptions had to be made.
First of all, we assumed no heterogeneity in the relative effects of aspirin for either benefits or
harms. This assumption is based on the results of the meta-analyses by Berger, Flossmann and
Rothwell. [1,10,13,18,21] We additionally assumed that the relative effects of aspirin on bene-
fits and harms did not vary between men and women[1,8,25] and that they were constant over
time. We assumed that all cases of myocardial infarction were all of the same severity, that all
strokes were severe, and that all episodes of major bleeding were major upper or lower gastro-
intestinal bleeds. We assumed that all cancers were equally severe.
Statistical analysis
Summary index for benefits and harms. The Gail/NCI approach19 considers multiple
patient-important outcomes of a medical intervention and provides profile-specific estimates
of the benefit-harm balance. In other words, the Gail/NCI approach provides a quantitative
benefit-harm comparison that indicates whether treatment compared to no treatment will
lower or increase the incidence of patient-important outcomes, over a specified period of time
for patients of a specific age and sex. An index>0 means that the benefits outweigh the harms;
an index<0 indicate more harms than benefits. The probabilities refers to the probability that
a specific index (e.g. for men with 55–64 years of age) is positive.
Necessary calculations are described below. In a first step we calculated the number of
events for each of the outcomes described above, expressed per 1,000 subjects over 10 years,
using mortality and incidence rates. We used the following equation
Nx; p ¼ 1; 000
n
ðIx =

Ix þ M
o

h
1 expf10

Ix þ M

g
i
ð1Þ
where Nx,p is the number of events for a speciﬁc outcome (x) per 1000 subjects over 10 years
in subjects without aspirin, Ix is the incidence of the event of interest, and M is the all-cause
mortality.
We then calculated the corresponding number of events with aspirin, again for each of the
outcomes, also expressed per 1,000 subjects over 10 years. We used
Nx; t ¼ 1; 000
n
ðRx  Ix =

Rx  Ix þ M
o

h
1 expf10

Rx  Ix þ M

g
i
ð2Þ
where Rx represents the treatment effect of aspirin on the respective outcome.
Then we calculated the Nx, the difference in number of events per 1,000 over 10 years based
on Eq (1) and (2).:
Nx ¼ Nx ; p Nx ; t ð3Þ
For benefits, Nx is positive: it expresses the number of events prevented by aspirin. For
harms, Nx is negative: it expresses the number of additional events induced by the use of aspi-
rin, per 1,000 subjects over 10 years.
The final benefit-harm index is based on summing of all events:
Index ¼
X
Wx  Nx ð4Þ
where W1 expresses the relative weight attached to the ﬁrst outcome, W2 to the second, and so
for all outcomes considered. In the main analysis we used equal weights for all outcomes. The
index is an absolute measure of the beneﬁt-harm balance.
A Benefit and Harm Analysis
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To take into consideration the sampling variability for the treatment effect estimates we
used a Bayesian approach and simulations to estimate the posterior probability that the index
is positive[19]. A probability of>50% means that that the benefits are greater than the harms
(index positive).
Main and sensitivity analyses
In the main analysis we used a weight of 1.0 for MI, stroke and gastrointestinal bleeding. Since
we had multiple cancer outcomes that may not occur independently from one another we used
a weight of 0.5 instead of 1.0 for cancers in order not to overestimate the benefits of aspirin.
We conducted four sensitivity analyses to consider variations in the data sources for outcome
risks and importance of outcomes. In the first sensitivity analysis we used different weights in
Eq (4). Weights were assigned according to the estimated five year survival as an indicator of
the importance of the outcomes (Table 2). [1,13,16,22–25] In the absence of five year data we
conservatively took available three year survival data for GI bleeding. Weights of 1.0, 0.5 or 0.1
were assigned to, 0% to 50%, 50% to 80% and 80% or higher five year survival rates, respec-
tively. Again, we divided the weights for cancers outcomes by two because of multiplicity and
in order not to overestimate the benefits of aspirin.
In the second sensitivity analysis we used treatment effects for overall cancer risk, because
overall incidence rates of cancer are higher than the sum of the separate cancers. We used a
meta-analysis reported by Rothwell.[9,25,26] The summary estimate for overall cancer was an
OR of 0.75 (95% CI 0.59;0.94) for women and 0.77 (95% CI 0.63;0.93) for men. In the third
sensitivity analysis we used again treatment effects for overall cancer risk and weights of 0.5 for
MI, 1.0 for stroke, 0.5 for gastrointestinal bleeding and 1.0 for overall cancer.
In the fourth sensitivity analysis we used data from RCT’s for the incidence rate estimates,
because outcome risks from control groups in trials are often used to calculate the absolute
effect of treatments. However, we considered these control group outcome risks (Table 1) only
a sensitivity analysis, since RCT participants are often selected and may not represent the out-
come risks in a general population. As an example, most RCTs excluded people with prior gas-
trointestinal bleeds. Data were not available for the four age categories. Mean participant age in
the RCT considered ranged from 53 to 65, which is comparable to the age category 55–64.
Table 2. Weights used in the first sensitivity analysis, based on 5-year survival.
Male Female Weight
Colorectal cancer(22,25) 65% 64% 0.25
Lung cancer(24,25) 14% 19% 0.5
Bladder cancer(24,25) 80% 73% 0.25
Stomach cancer(23,25) 24% 28% 0.5
Pancreas cancer(5,25) 5.4% 6.0% 0.5
Oesophagus cancer(9,25) 18% 17% 0.5
Prostate/Breast Cancer (25,28) 99% 89% 0.05
Myocardial infarction(13,22) 79% 79% 0.25
Haemorrhagic stroke(15,24) 42% 42% 0.5
Ischemic stroke(1,24) 42% 42% 0.5
Gastrointestinal bleeding(23,34) 63% 63% 0.25
doi:10.1371/journal.pone.0127194.t002
A Benefit and Harm Analysis
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Results
Table 3 shows the number of expected events over 10 years for 1,000 men and women, with
and without aspirin. For example, in men between 55 and 64 years the expected cases of
myocardial infarctions in those taking aspirin would be 49 per 1,000 over 10 years. In the same
age group we expect 57 myocardial infarctions in 1,000 men not taking aspirin, also over 10
years. In Table 4 the numbers of expected events with and without aspirin are shown as well as
the results of the sensitivity analyses. In the main analysis, the index (positive if prevented ben-
efit events> excess harm events over 10 years per 1,000 persons) ranged from 2 (95% CI
(-0.1;22.2)) in men with age 45 to 54 years to 8 (95% CI -0.1;83.7)) in men with age 65 to 74
years. In the sensitivity analyses, the index was also positive for all age categories suggesting
more benefits than harms but again the 95% CI were relatively wide. Probabilities that the
index is positive were all above 95%.
Table 3. Expected number of events without and with aspirin prevention in men and women.*
Number of expected events over 10 years per 1,000 men
Men
Age (years) 45–54 55–64 65–74 75–84
Aspirin (no or yes) No Yes No Yes No Yes No Yes
Myocardial infarction 38 33 57 49 79 68 96 83
Cancer overall 81 61 188 144 352 279 295 233
Colorectal Cancer 9 6 20 13 39 25 46 30
Lung Cancer 9 9 31 29 70 67 79 76
Bladder Cancer 3 3 11 10 28 26 41 39
Stomach Cancer 1 1 4 4 7 7 8 9
Pancreas Cancer 2 2 5 6 10 11 13 13
Esophageal Cancer 1 1 4 3 7 5 7 5
Prostate Cancer 20 17 84 74 148 130 105 92
Major ischemic stroke 12 10 24 20 48 42 75 66
Major haemorrhagic stroke 2 3 4 5 7 10 12 16
Major gastrointestinal bleeding 12 19 24 38 42 68 56 89
Women Number of expected events over 10 years per 1,000 women
Age (years) 45–54 55–64 65–74 75–84
Aspirin (no or yes) No Yes No Yes No Yes No yes
Myocardial infarction 12 10 29 25 42 37 63 54
Cancer overall 95 74 160 126 240 191 251 201
Colorectal Cancer 12 8 14 9 28 18 39 25
Lung Cancer 8 8 23 22 51 49 53 51
Bladder Cancer 1 1 3 3 7 7 10 10
Stomach Cancer 1 1 2 2 3 3 5 5
Pancreas Cancer 1 1 4 4 8 9 12 12
Esophageal Cancer 0 0 1 1 2 1 2 2
Breast cancer 13 11 16 14 18 16 12 11
Major ischemic stroke 9 8 19 17 33 29 58 50
Major haemorrhagic stroke 1 1 3 4 5 6 9 12
Major gastrointestinal bleeding 6 10 12 19 21 34 29 46
*All-cause mortality is considered as a competing risk.
doi:10.1371/journal.pone.0127194.t003
A Benefit and Harm Analysis
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Discussion
In this study we have assessed profile-specific estimates for the benefits and harms of using
aspirin for primary prevention in cardiovascular disease and cancer. Several methods for bene-
fit-harm analyses exist, we chose to use the Gail/NCI approach. The Gail/NCI approach con-
siders all key elements to estimate a benefit-harm balance; it considers scientific evidence on
treatment effects, patient characteristics with associated risks of outcomes and considers the
preferences for these outcomes. The outcome, an index with a probability estimate is likely to
be useful in decision making. Our analyses suggest, irrespective of how much weight we
assigned to the different outcomes, that in the general US population between 40 and 85 years
of age the overall benefits of the use of aspirin as a primary prevention tool when considering
outcomes of cancer, cardiovascular risk and gastrointestinal bleeding, are greater than the
harms. Whether these results should lead to public health action or revision of some guideline
recommendations depends on the context and on cost issues. In our view, the benefit harm
index—and probabilities for net benefit associated with it—are but one component informing
decisions; other factors also require consideration.
Some limitations need to be addressed. Assumptions have to be made in benefit-harm anal-
yses. In quantitative benefit-harm analyses the importance of the selection of data and sensitiv-
ity analyses cannot be stressed too much. The analyses consistently show a consistent overall
benefit of aspirin but there are differences in the magnitude of the index across the main and
sensitivity analyses. For example, the choice of weights for the outcomes is often arbitrary.
However, quantitative approaches like the Gail/NCI approach contribute to understanding
Table 4. Benefit-harms comparison index for primary prevention of cardiovascular events and cancer with low dose aspirin over 10 years per
1,000 persons (95%CI and probability that index is positive based on recalculating the index in simulations).
Men Women
45–54 (95%
CI;
probability)
55–64(95%
CI;
probability)
65–74(95%
CI;
probability)
75–84(95%
CI;
probability)
45–54(95%
CI;
probability)
55–64(95%
CI;
probability)
65–74(95%
CI;
probability)
75–84(95%
CI;
probability)
Main analysis 1 Type
speciﬁc cancer
rateSame weights for
all outcomes
2 (-0.1, 22.2;
97%)
5 (0.1, 47.9;
98%)
8 (-0.1, 83.7;
97%)
3 (-0.2, 97.7;
97%)
2 (0.0, 11.8;
98%)
2 (0.1, 24.0;
98%)
3 (-0.2, 41.0;
97%)
4 (0.1, 57.3;
98%)
Sensitivity analysis 1;
Type speciﬁc cancer
rateWeights based on
ﬁve year survival
1 (0.0, 12.7;
98%)
2 (0.1, 26.1;
98%)
3 (-0.1, 47.5;
97%)
3 (-0.2, 61.1;
97%)
1 (0.0, 7.2;
97%)
2 (0.0, 15.9;
97%)
3 (0.0, 28.5;
98%)
4 (0.1, 40.9;
98%)
Sensitivity analysis 2;
Overall cancers
ratesSame weights for
all outcomes
18 (0.1, 36.6;
98%)
38 (0.2, 72.6;
98%)
62 (0.3,
120.9; 98%)
55 (0.4,
133.3; 98%)
20 (0.1, 30.8;
98%)
33 (0.2, 54.9;
98%)
45 (0.2, 81.7;
98%)
46 (0.3, 97.5;
98%)
Sensitivity analysis 3;
Overall cancer
ratesWeights based
on ﬁve year survival
19 (0.1, 30.2;
98%)
42 (0.2, 62,3;
98%)
69 (0.3,
105.6; 98%)
66 (0.4,
114.2; 98%)
21 (0.1, 28.5;
98%)
34 (0.2, 49.8;
98%)
48 (0.2, 73.6;
98%)
50 (0.3, 85.8;
98%)
Sensitivity analysis 4;
Outcome risks based
on control groups
from RCTsSame
weights for all
outcomes
14 (0.0, 22.4; 97%) 3 (0.0, 10.4; 98%)
1Positive values = aspirin beneﬁcial; Negative values = aspirin harmful
doi:10.1371/journal.pone.0127194.t004
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how much different weights change the overall benefit harm balance. Furthermore, sensitivity
analyses give an opportunity for exploring the impact of characteristics such as age, gender or
other prognostic indicators. The use of transparent quantitative approaches where the data
sources are clearly presented offers an opportunity to illustrate how different opinions about
the appropriate selection of data sources impact on the overall benefit-harm balance.[17,20]
To our knowledge, our study is the first to assess the combined effect of aspirin for primary
prevention of both cardiovascular disease and cancer in a single quantitative benefit-harm
analysis. The effect of aspirin on cardiovascular disease has been studied for decades whereas
the preventable effect in cancer has been studied more recently. Meta-analyses have been con-
ducted for several types of cancer, showing a protective effect for aspirin in the development of
cancer.[1,2,4,13,15], Berger et al. conducted a meta-analysis to investigate the effect of aspirin
on cardiovascular disease and harms and concluded that there was only a modest support for
benefit of aspirin in patients without cardiovascular disease.[1,26,32] A meta-analysis of Sesha-
sai et al. [33,34] showed that aspirin in primary prevention does decrease the risk of MI, but
that aspirin does not lead to lower cancer mortality and increases the risk of bleeding. Our data
show that cancer incidence is modestly decreased and that the risks of bleeding are smaller
than the benefits of taking aspirin. By conducting a quantitative benefit-harm analysis a more
precise estimate of the benefits and harms could be made. By including cancer and more pre-
cisely several subtypes of cancer into our analyses we provide a more comprehensive estimate
of the benefit to harm ratio, instead of only including cardiovascular disease.
In 2005, 23% of 45 to 64 year olds without heart disease in the US took aspirin on a daily or
every other day basis. Recommendations on aspirin do not entirely agree in major guidelines
For example, the American College of Chest Physicians (ACCP) (2012) suggest the use of aspi-
rin for persons over age 50 without symptomatic cardiovascular disease, while the US Preven-
tive Services Task Force encourages the use of aspirin in selected populations only (men 45–79
for the prevention of MI and women 55–79 for the prevention of stroke) who are not at ele-
vated risk for bleeding. [5] Except for the US Preventive Services Task Force guideline, the
guidelines only take the benefits of aspirin explicitly into account while the consideration of
harms, is not made entirely clear. The inconsistencies in recommendations and how to con-
sider both benefits and harms of aspirin may be a consequence of not using formal methods
for quantitative benefit-harm analyses. Putting the preventive effects of aspirin as estimated
from RCTs into the context of various outcome risks and importance of outcomes is a complex
task but analyses such as ours may help. While we do not want to make recommendations
about aspirin, our analyses show that it is possible to deal with the multidimensional issue of
aspirin for primary prevention in a transparent way. The use of quantitative benefit-harm anal-
ysis, where the data used are explicitly described and assumptions are tested in sensitivity anal-
yses, could lead to a better understanding if and for whom a preventive intervention should be
recommended or not. It is relatively straightforward to repeat the analyses using different treat-
ment effects, outcome risks and preferences (importance of outcomes) depending on the deci-
sion making context. Thereby, the impact of using different data and assumptions on the
benefit-harm balance can be tested. These sensitivity analyses are useful because they inform
developing the strength of a recommendation. If the sensitivity analyses show similar results
favoring a preventive intervention a guideline panel may issue a strong recommendation. In
turn, if the sensitivity analyses show different results, the recommendation may be weak for or
against the intervention.
We must consider that our analyses were made from a population perspective. For some
individual patients, with individual circumstances such as increased risk for gastrointestinal
bleeding, aspirin may be associated with more harms than benefits. The risk for gastrointestinal
bleeding is increased by older age, prior gastrointestinal events, the use of non-steroidal anti-
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inflammatory agents and in males.[29] The US preventive Services Task Force recommended
that decisions on individual patients should be made on the basis of these risk factors. The
Task Force recommends the use of aspirin as a preventive tool when the potential benefit of a
reduction in myocardial infarctions outweighs the potential harm of an increase in bleeding.
Although the guideline refers to the use of risk prediction models[28], it does not give explicit
guidance on how to estimate the balance between harms and benefits for individuals. [5]
This study suggests an overall benefit of aspirin for primary prevention of cardiovascular
disease and cancer based on population-based data. For preventive counseling, additional ben-
efit-harm analyses should explore which individuals should or should not take aspirin based
on their risk profile for cardiovascular, cancer and gastrointestinal outcomes and based on
their outcome preferences. Thereby, risk-stratified and preference-sensitive prevention could
become a reality.
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